News
Eli Lilly and Pfizer discontinue the global clinical development program for tanezumab, an investigational nerve growth factor inhibitor.
Q3 financial statement from Eli Lilly: In October 2021, Eli Lilly and Pfizer discontinued the global clinical development program for tanezumab, an investigational nerve growth factor inhibitor.
This decision was made following receipt of a Complete Response Letter from the FDA for the tanezumab application in osteoarthritis (OA) and a negative opinion adopted by the European Medicines Agency's Committee for Medicinal Products for Human Use on the tanezumab Marketing Authorization Application in OA.
Condition: Pain:Osteoarthritis
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins